Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 2b open-label & single-arm study to evaluate pharmacokinetics& efficacy& safety and tolerability of letermovir in pediatric participants from birth to <18 years of age at risk of developing CMV infection and/or disease following allogeneic HSCT
Protocol ID
MK-8228-030
Disease (Sub Disease)
Cytomegalovirus (CMV) Infection
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Relapse/Refractory
Sponsor
Merck Sharp & Dohme Corp.
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 2
Age Eligibility
up to 17 years
International registry ID's
NCT03940586
| Study Title | A Phase 2b open-label & single-arm study to evaluate pharmacokinetics& efficacy& safety and tolerability of letermovir in pediatric participants from birth to <18 years of age at risk of developing CMV infection and/or disease following allogeneic HSCT |
|---|---|
| Protocol ID | MK-8228-030 |
| Disease (Sub Disease) | Cytomegalovirus (CMV) Infection |
| Diagnosis Stage | New Diagnosis Relapse/Refractory |
| Sponsor | Merck Sharp & Dohme Corp. |
| Links | https://clinicaltrials.gov/ct2/show/NCT03940586 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 08/08/2019 |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | up to 17 years |
| International registry ID's | NCT03940586 |